App-Quantinova.ai

Healthcare Resource Utilization and Costs of Multiple Sclerosis in Canada by Disability (P3.405)

Luanne Metz - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Conventional imaging can still predict neurodevelopmental outcome in asphyxiated newborns treated with hypothermia (P3.187)

Fatema Amrani - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

RNA-seq for the diagnosis of inherited myopathies: a pilot study (S54.002)

Stefan Nicolau - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Autonomic denervation of brain vessels in patients with NOH (P5.325)

Juan Manuel Racosta - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

N/A

Suloctidil

Treatment with interferon reduces the appearance of lesions in clinically relevant white matter (WM) tracts in patients with clinically isolated syndrome (CIS) (P6.340)

Marco Battaglini - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon

Alzheimer’s Disease: 3-Dimensional MRI-texture for Prediction of Conversion from Mild Cognitive Impairment (S35.006)

Collin Luk - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Headache is a Common and Disabling Comorbidity in People with Clinically Isolated Syndrome (P3.358)

Wei-Qiao Liu - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Minocycline

Evaluation of Respiratory Testing for Patients with Myasthenia Gravis in the Neuromuscular Clinic (P3.112)

Hans Katzberg - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Communication gaps on OFF periods in Parkinson’s disease: A linguistic patient-physician dialogue analysis (P6.015)

David Squillacote - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Money is Brain: Financial Barriers and Consequences for Canadian Stroke Patients (P6.267)

Aravind Ganesh - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Pharmacokinetic Modeling Study to Evaluate Two Intranasal Formulations of Sumatriptan for Nasal vs Gastrointestinal Tract Absorption (P2.147)

Mary Lor - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Sumatriptan

MCAM in Multiple Sclerosis: a biomarker of disease activity? (P1.381)

Alexandra Muccilli - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Achieving the optimal profile for Alzheimer’s immunotherapy: Rational generation of antibodies specific for toxic Aβ oligomers (P6.084)

Steven Plotkin - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with Multiple Sclerosis (P3.370)

Sarah Anne Morrow - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Detrol

Mental imagery strategy and body position effects on imagining gait in healthy young and old adults: results from a cross-sectional study (P6.094)

Harmehr Sekhon - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Utilization of Carotid Revascularization for Ischemic Stroke/TIA: A Canadian Perspective (P5.276)

Mohamed Najm - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

High Pulse Pressure and Hypertension are Independently Associated with Cognitive Impairment in Early Untreated Parkinson’s Disease (P2.094)

Maxime Doiron - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

The state of the art of technologies for the assessment of gait in multiple sclerosis: Filling the gap (P1.378)

Stephen Czarnuch - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Development of a new instrument to discriminate orthostatic from non-orthostatic symptoms: The Orthostatic Discriminant and Severity Scale (P5.324)

Jacquie Baker - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Tissue-engineered skin model derived from neurofibromatosis type 1 (NF1) patients to study tumor genesis and to predict response to therapy (P4.057)

Vincent Roy - American Academy of Neurology (AAN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Filters

28841 Abstracts